NCT05418127进行中（未招募）不适用
A Randomized, Double-blinded, Placebo-controlled, Parallel Study, to Assess the Effect of Traditionally Fermented Organic Coconut Milk Kefir on Gastrointestinal Symptoms in Healthy Adults
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Change in proportion of Participants who report a change in the maximum severity of their bloating in a daily eDiary.
研究概览
简要总结
A randomized, double-blinded, placebo-controlled, parallel study, to evaluate the effect of 8-week supplementation of a traditionally fermented organic coconut milk kefir compared to placebo on gastrointestinal symptoms in healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Only one representative of sponsor and two Atlantia Clinical Trials representatives are unmasked.
入排标准
- 年龄范围
- 25 Years 至 54 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Willing to participate in the study and comply with its procedures, including but not limited to consuming study product, adhering to visit schedule and e-diary/questionnaires, abstaining from products outlined in Section 5.8 of Study Protocol.
- •Able and willing to give written informed consent.
- •Adults aged between 25 to 54 years, inclusive.
- •Self-reported bloating on at least 3 occasions over the 7-day period immediately prior to enrolment (confirmed by selecting any option other than 'None' in response to the daily electronic diary Bloating question in the electronic diary questionnaire completed prior to enrolment).
排除标准
- •Participants who are pregnant or wish to become pregnant during the trial.
- •Participants who are lactating and/or currently breastfeeding.
- •Participants currently of childbearing potential, but not using an effective method of contraception for at least 30 days prior to dosing, as outlined below:
- •Complete abstinence from intercourse prior to administration of the study product, throughout the clinical trial, until the completion of follow-up procedures or for two weeks following discontinuation of the study product in cases where participant discontinues the trial prematurely. (Participants utilising this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for the Final Visit).
- •Has a male sexual partner who is surgically sterilised prior to the Screening Visit and is the only male sexual partner for that participant.
- •Sexual partner(s) is/are exclusively female.
- •Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g. male condom, female diaphragm), or contraceptive pill/patch/injection/ring. The participant must be using this method for at least 30 days prior to and 2 weeks following the end of the trial.
- •Use of any intrauterine device (IUD) or contraceptive implant. The participant must have the device inserted at least 30 days prior to the first Screening Visit, throughout the trial, and 2 weeks following the end of the trial.
- •Participants who have a history of histamine intolerance (i.e., intolerance to fermented food) or any known coconut or tree nut allergy.
- •Participants who have consumed prebiotic or probiotic supplements in the 14 days prior to screening (Visit 1).
- •Participants have consumed fermented coconut/kefir products in the 14 days prior to screening (Visit 1) and are intending to consume such products during the course of the trial.
- •Participants who have used oral antibiotics in the 90 days prior to screening (Visit 1).
- •Participants who have had gastrointestinal surgery (e.g., colectomy, gall bladder removal, gastric bypass) - appendectomy not considered an exclusionary surgery.
- •Participants who have any significant health conditions or current medications that would prevent them from fulfilling the trial requirements, put the Participant at risk or would confound the interpretation of the trial results as judged by the investigator on the basis of medical history, medication history, and routine laboratory test results.
- •Participants who cannot safety stop taking prescription medication for the duration of the trial
- •Participants may not be receiving treatment involving experimental drugs. If the Participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to screening (Visit 1).
- •Participants who have used any immunosuppressant or chemotherapy medications, including marcaptopurine, azothioprine, or methotrexate in the last 5 years.
- •Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
- •Any Participant who is an employee of the investigational site or an Atlantia Clinical Trials employee or their close family member or a member of their household.
结局指标
主要结局
Change in proportion of Participants who report a change in the maximum severity of their bloating in a daily eDiary.
时间窗: 8 weeks
To evaluate in healthy adults who experience gastrointestinal bloating or distention the effect of 8-week supplementation of a fermented coconut milk kefir compared to Placebo on the severity of bloating from baseline to Week 8 (confirmed by selecting a lower category of severity of bloating during the 7-day period prior to end of intervention compared to the 7-day period prior to Baseline on the day with their worst symptom rating).
次要结局
- Change in mean daily severity of Abdominal Pain symptoms of Participants (as recorded in the daily e-diary Abdominal Pain question).(8 weeks)
- Change in proportion of Participants experiencing Flatulence/Gas symptoms (selecting any option other than 'None' in response to the daily e-diary Flatulence/Gas question).(8 weeks)
- Change in mean daily severity of Abdominal Discomfort symptoms of Participants (as recorded in the daily e-diary Abdominal Pain question).(8 weeks)
- Difference between product groups of self-reported symptom improvement from the Global Impression of Change Scale at end of intervention.(8 weeks)
研究者
Linda Peers
Principal Investigator
Coconut Goodness Food Products Inc.
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Effects of Bifidobacterium Longum 1714® in a Population With Low MoodLow MoodDepressive SymptomsNCT04925440PrecisionBiotics Group Ltd.168
已完成
1 期
Combination Herbal Therapy (CHT) Versus Placebo in Patients With Irritable Bowel Syndrome (IBS)Colonic Diseases, FunctionalNCT00130741Hadassah Medical Organization100
招募中
3 期
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar DepressionDepression, BipolarNCT03423680Korea Otsuka Pharmaceutical Co., Ltd.390
已完成
4 期
A Study Evaluating Duloxetine in Patients Hospitalized for Severe DepressionMajor Depressive DisorderNCT00422162Eli Lilly and Company339
已完成
不适用
Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of ImmunityImmunityNCT02244372Chonbuk National University Hospital90